Product image of Minirin/Ddavp (Desmopressin Acetate) supplied by GNH India

Minirin/Ddavp

Active Ingredient:
Desmopressin Acetate
Origin:
EU

Minirin/Ddavp (Desmopressin Acetate)

Desmopressin acetate, the active ingredient in Minirin/Ddavp, is a vasopressin analog presented as a nasal spray for nasal use. It treats central diabetes insipidus, nocturnal enuresis, primary nocturnal polyuria and helps control bleeding in hemophilia A. GNH India supplies Minirin/Ddavp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ferring S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Minirin/Ddavp acts on the antidiuretic hormone pathway to manage disorders of water balance and bleeding.
  • Central diabetes insipidus: reduces excessive urine output by enhancing water reabsorption in the kidneys.
  • Nocturnal enuresis: decreases nighttime bedwetting episodes through improved urinary concentration.
  • Primary nocturnal polyuria: lowers nighttime urine volume, helping maintain dry nights.
  • Hemophilia A (to control bleeding): raises plasma factor VIII and von Willebrand factor levels, aiding clot formation.

How It Works

  • Desmopressin acetate is a selective V2‑receptor agonist that binds to vasopressin receptors in the renal collecting ducts, stimulating insertion of aquaporin‑2 channels and increasing water reabsorption. In the vascular endothelium, it promotes release of factor VIII and von Willebrand factor, enhancing haemostatic activity. The combined renal and haemostatic actions underlie its therapeutic effects.

Side Effects

Adverse reactions may occur with any use of desmopressin nasal spray.

Common Side Effects

  • Nasal irritation or congestion
  • Headache
  • Mild hyponatremia
  • Thirst or dry mouth
  • Nausea
  • Mild dizziness

Serious or Rare Side Effects

  • Severe hyponatremia leading to seizures or coma
  • Water intoxication with pulmonary edema
  • Allergic reactions such as rash or angioedema
  • Significant hypotension
  • Thrombotic events in predisposed patients
  • Acute renal failure in extreme cases

Precautions & Warnings

  • Before initiating therapy, clinicians should consider several safety measures.
  • Monitor serum sodium: check electrolytes regularly, especially in high‑risk patients.
  • Adjust fluid intake: advise patients to limit excessive water consumption.
  • Use caution in renal impairment: assess kidney function prior to prescribing.
  • Avoid in uncontrolled hyponatremia: contraindicated when serum sodium is already low.
  • Use with caution in the elderly: increased susceptibility to hyponatremia.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Desmopressin may interact with several drug classes.

Major Interactions (Avoid)

  • Carbamazepine: reduces desmopressin efficacy.
  • Thiazide diuretics: increase risk of hyponatremia.
  • NSAIDs: may potentiate water retention.
  • Other ADH analogues: risk of severe hyponatremia.
  • SSRIs: heightened hyponatremia risk.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: monitor blood pressure and electrolytes.
  • Anticoagulants (e.g., warfarin): observe bleeding parameters.
  • Other antidiuretic agents: dose adjustment may be needed.
  • Hormonal contraceptives: may affect fluid balance.
  • CYP450 inducers (e.g., rifampin): may lower plasma levels of desmopressin.

Frequently Asked Questions

Minirin/Ddavp is a prescription nasal spray containing desmopressin acetate. It is used to treat central diabetes insipidus, reduce nighttime bedwetting in nocturnal enuresis, manage primary nocturnal polyuria, and control bleeding in patients with hemophilia A by increasing clotting factor levels.

Desmopressin acetate selectively activates V2 receptors in the kidney, promoting insertion of aquaporin‑2 water channels in the collecting ducts, which enhances water reabsorption. It also stimulates release of factor VIII and von Willebrand factor from endothelial cells, improving haemostasis.

The exact dose of Minirin/Ddavp is determined by the prescribing clinician based on the individual’s condition, age, weight and response. Typical regimens start with a low number of sprays and are adjusted as needed, but the specific schedule should always follow the prescriber’s instructions.

Safety data for desmopressin acetate during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To order Minirin/Ddavp, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Minirin/Ddavp (desmopressin) is a synthetic analogue of natural vasopressin but has a longer half‑life and greater selectivity for V2 receptors, resulting in stronger antidiuretic effects with fewer vasoconstrictive actions. Compared with natural vasopressin, it offers more predictable dosing and a lower risk of cardiovascular side effects.

Store Minirin/Ddavp at ambient temperature, below 25 °C, in the original sealed container. Protect the nasal spray from moisture, direct sunlight and extreme temperatures. Do not freeze the product, and keep it out of reach of children.

Minirin/Ddavp is administered as a nasal spray. The patient should prime the device if it is new, then tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The other nostril can be used for subsequent sprays if required.

The most serious risks include severe hyponatremia, which can lead to seizures, coma, or death, and water intoxication causing pulmonary edema. Patients should be monitored for sudden changes in mental status, severe headache, nausea, vomiting, or swelling, and serum sodium should be checked regularly.

Minirin/Ddavp should not be used in patients with uncontrolled hyponatremia, severe renal impairment, or known hypersensitivity to desmopressin acetate. Caution is also advised for individuals with a history of water intoxication, chronic heart failure, or those taking interacting medications that markedly increase the risk of hyponatremia.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Desmopressin Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT